Table 1 Clinical and demographic data
No | % | |
|---|---|---|
Age (years) | ||
< 5 | 3 | 3.7 |
5–9.99 | 23 | 28.8 |
≥ 10–16 | 54 | 67.5 |
Gender | ||
Male | 45 | 56.3 |
Female | 35 | 43.7 |
B symptoms | ||
No | 46 | 57.5 |
Yes | 34 | 42.5 |
Primary site | ||
Peripheral lymph nodes | 65 | 81.25 |
Mediastinum | 15 | 18.75 |
Bulky | ||
No | 59 | 73.8 |
Yes | 21 | 26.2 |
Extra nodal involvement | ||
No | 51 | 63.8 |
Yes | 29 | 36.2 |
Epstein-Barr virus | ||
Positive | 40 | 50 |
Negative | 5 | 6.3 |
N/A | 35 | 43.7 |
Pathology | ||
Classic Hodgkin’s lymphoma | ||
Lymphocyte rich | 9 | 11.25 |
Mixed cellularity | 18 | 22.5 |
Nodular sclerosis | 44 | 55 |
Lymphocyte depleted | 0 | 0 |
Nodular lymphocyte predominant Hodgkin’s lymphoma | 9 | 11.25 |
Stage | ||
I | 5 | 6.3 |
II | 25 | 31.2 |
III | 42 | 52.5 |
IV | 8 | 10 |
Early and advanced stages | ||
Early (I, II) | 30 | 37.5 |
Advanced (III, IV) | 50 | 62.5 |
Risk group | ||
Low | 12 | 15 |
Intermediate | 44 | 55 |
High | 24 | 30 |
Laboratory data: median (range) | ||
WBC (× 109/l) | 7.4 (2.3–31.6) | |
HGB (× 109/l) | 11.8 (6.1–15.2) | |
PLT (× 109/l) | 357 (27–856) | |
LDH (μ/l) | 266.5 (131–1164) | |